Modulating the p53 pathway.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Seminars in Cancer Biology

• Publication date

  2010-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.semcancer.2010.02.004PMID 20193765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification and Characterization of the First Small Molecule Inhibitor of MDMX*

  2010cited by this paper
• Awakening guardian angels: drugging the p53 pathway

  2009cited by this paper
• A complex barcode underlies the heterogeneous response of p53 to stress

  2008cited by this paper
• p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.

  2008cited by this paper
• p53 mRNA controls p53 activity by managing Mdm2 functions

  2008cited by this paper
• Mitochondria in cancer cells: what is so special about them?

  2008cited by this paper
• Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

  2008cited by this paper
• Structural biology of the tumor suppressor p53.

  2008cited by this paper
• iASPP inhibition: increased options in targeting the p53 family for cancer therapy.

  2008cited by this paper
• TP53 Status and Response to Chemotherapy in Breast Cancer

  2008cited by this paper
• The ever-lengthening arm of p53.

  2008cited by this paper
• Turning a scorpion toxin into an antitumor miniprotein.

  2008cited by this paper
• Stability and structural recovery of the tetramerization domain of p53-R337H mutant induced by a designed templating ligand

  2008cited by this paper
• Updates on p53: modulation of p53 degradation as a therapeutic approach

  2008cited by this paper
• Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

  2008cited by this paper
• The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

  2008cited by this paper
• HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function

  2008cited by this paper
• Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

  2008cited by this paper
• PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity

  2008cited by this paper
• Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26.

  2008cited by this paper
• Detection of the p53 response in zebrafish embryos using new monoclonal antibodies

  2008cited by this paper
• Molecular simulations of protein dynamics: new windows on mechanisms in biology

  2008cited by this paper
• Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway

  2008cited by this paper
• Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2

  2008cited by this paper
• Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells

  2008cited by this paper
• Targeting p53 to mitochondria for cancer therapy

  2008cited by this paper
• Therapeutic prospects for p73 and p63: rising from the shadow of p53.

  2008cited by this paper
• Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain

  2008cited by this paper
• Restoration of p53 to limit tumor growth

  2008cited by this paper
• Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73.

  2008cited by this paper
• MDM2 and MDM4: p53 regulators as targets in anticancer therapy.

  2007cited by this paper
• R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy

  2007cited by this paper
• PACT is a negative regulator of p53 and essential for cell growth and embryonic development

  2007cited by this paper
• A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo.

  2007cited by this paper
• Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6

  2007cited by this paper
• microRNAs join the p53 network — another piece in the tumour-suppression puzzle

  2007cited by this paper
• p53 in health and disease

  2007cited by this paper
• Ubiquitination and Degradation of Mutant p53

  2007cited by this paper
• Restoration of p53 function leads to tumour regression in vivo

  2007cited by this paper
• Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator

  2007cited by this paper
• Regulation of p53 tetramerization and nuclear export by ARC

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination

  2007cited by this paper
• The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.

  2007cited by this paper
• Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

  2007cited by this paper
• Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide

  2007cited by this paper
• MDM2 inhibitors for cancer therapy.

  2007cited by this paper
• Nutlin-3 inhibits the NFκB Pathway in a p53 Dependent Manner: Implications in Lung Cancer Therapy

  2007cited by this paper
• Abstract 313: Regulation of p53 Tetramerization and Nuclear Export by ARC

  2006cited by this paper
• MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

  2006cited by this paper
• p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress

  2006cited by this paper
• Modeling the therapeutic efficacy of p53 restoration in tumors.

  2006cited by this paper
• The pathological response to DNA damage does not contribute to p53-mediated tumour suppression

  2006cited by this paper
• Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2

  2006cited by this paper
• Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

  2006cited by this paper
• The P53 pathway: what questions remain to be explored?

  2006cited by this paper
• Prospective therapeutic applications of p53 inhibitors.

  2005cited by this paper
• PUMA Couples the Nuclear and Cytoplasmic Proapoptotic Function of p53

  2005cited by this paper
• An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

  2005cited by this paper
• P53 and prognosis: new insights and further complexity.

  2005cited by this paper
• Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA.

  2004cited by this paper
• The ubiquitin ligase COP1 is a critical negative regulator of p53

  2004cited by this paper
• China approves first gene therapy

  2004cited by this paper
• Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

  2004cited by this paper
• The p53 paddy wagon: COP1, Pirh2, and MDM2 are found resisting apoptosis and growth arrest

  2004cited by this paper
• A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

  2004cited by this paper
• Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• A big step in the study of small cell lung cancer.

  2003cited by this paper
• Drug discovery and p53.

  2003cited by this paper
• iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human

  2003cited by this paper
• Small molecules that reactivate mutant p53.

  2003cited by this paper
• Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.

  2003cited by this paper
• Replication of an E1B 55-Kilodalton Protein-Deficient Adenovirus (ONYX-015) Is Restored by Gain-of-Function Rather than Loss-of-Function p53 Mutants

  2003cited by this paper
• Rescue of mutant p53 transcription function by ellipticine

  2003cited by this paper
• A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants

  2002cited by this paper
• Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling.

  2002cited by this paper
• The Mdm2 gene of zebrafish (Danio rerio): preferential expression during development of neural and muscular tissues, and absence of tumor formation after overexpression of its cDNA during early embryogenesis.

  2000cited by this paper
• Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts.

  2000cited by this paper
• A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

  1999cited by this paper
• Zebrafish (Danio rerio) p53 tumor suppressor gene: cDNA sequence and expression during embryogenesis.

  1997cited by this paper
• ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

  1997cited by this paper
• p53, guardian of the genome

  1992cited by this paper
• Cancer. p53, guardian of the genome.

  1992cited by this paper

• The Role of the SIX Family in Cancer Development and Therapy: Insights from Foundational and Cutting-Edge Research.

  2025cites this paper
• Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

  2024cites this paper
• Evaluation of the Anticancer Effects of Allicin-Loaded Solid Lipid Nanoparticles in the A549 Lung Cancer Cell Line

  2024cites this paper
• PX-478 induces apoptosis in acute myeloid leukemia under hypoxia by inhibiting the PI3K/AKT/mTOR pathway through downregulation of GBE1.

  2024cites this paper
• Post-translational modification in the pathogenesis of vitiligo

  2024cites this paper
• Allium Vegetables Intake and Digestive System Cancer Risk: A Study Based on Mendelian Randomization, Network Pharmacology and Molecular Docking

  2024cites this paper
• Knockdown of hCINAP sensitizes colorectal cancer cells to ionizing radiation

  2024cites this paper
• The phosphorylation-deubiquitination positive feedback loop of the CHK2-USP7 axis stabilizes p53 under oxidative stress.

  2024cites this paper
• Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer

  2023cites this paper
• Prenatal cadmium exposure impairs neural tube closure via inducing excessive apoptosis in neuroepithelium.

  2023cites this paper
• A multi-omics approach based on 1H-NMR metabonomics combined with target protein analysis to reveal the mechanism of RIAISs on cervical carcinoma patients

  2022cites this paper
• Value of glycogen synthase 2 in intrahepatic cholangiocarcinoma prognosis assessment and its influence on the activity of cancer cells

  2021cites this paper
• Unique structural features of the adenylate kinase hCINAP/AK6 and its multifaceted functions in carcinogenesis and tumor progression

  2021cites this paper
• The potential risks of chronic fluoride exposure on nephrotoxic via altering glucolipid metabolism and activating autophagy and apoptosis in ducks.

  2021cites this paper
• Deacetylation of GD3A as a potential therapeutic strategy for paediatric medulloblastoma

  2016cites this paper
• Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis

  2016cites this paper
• Molecular mechanisms of etoposide

  2015cites this paper
• hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14

  2014cites this paper
• iTRAQ‐based proteomic analysis of dioscin on human HCT‐116 colon cancer cells

  2014cites this paper
• Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling

  2013cites this paper
• Screening and evaluation of traditional Chinese medicine by microarray expression analysis.

  2013cites this paper
• Dietary downregulation of mutant p53 levels via glucose restriction

  2012cites this paper
• Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation

  2012cites this paper
• Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

  2011cites this paper
• Jetzt wird es ernst: strukturbasiertes Design von Mdm2/Mdmx-p53-Inhibitoren

  2011cites this paper
• Edinburgh Research Explorer p21 (WAF1) is component of a positive feedback loop that maintains the p53 transcriptional program

  2011influential citation
• Title Multifactorial Origins of Heart and Gut Defects in nipbl-Deficient Zebrafish , a Model of Cornelia de Lange Syndrome Permalink

  2011cites this paper
• Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy.

  2011cites this paper
• The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

  2011cites this paper
• Modulation of YY1 and p53 expression by transforming growth factor-β3 in prostate cell lines.

  2011cites this paper
• p21WAF1 is component of a positive feedback loop that maintains the p53 transcriptional program

  2011influential citation
• Multifactorial Origins of Heart and Gut Defects in nipbl-Deficient Zebrafish, a Model of Cornelia de Lange Syndrome

  2011cites this paper
• Restoration of DNA‐binding and growth‐suppressive activity of mutant forms of p53 via a PCAF‐mediated acetylation pathway

  2010cites this paper